drugset / Trial / NCT00314509

Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)

NCT00314509

Phase 2 Completed 240 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma. The study duration consists of a baseline period (2 to 3 weeks) and a treatment period (8 weeks). The study will provide further data on safety and tolerability of ciclesonide/formoterol fumarate.

Timeline

Start
2005-07
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciclesonide Other / unclassified Inhaled
Subject Formoterol Other / unclassified Inhaled

Indications